The Scientific Imperative
A Century of Progress. A Decade Lost.
Life expectancy surged by more than 30 years across the 20th century — driven by antibiotics, vaccines, insulin, statins, and more recently GLP-1 receptor agonists now demonstrating reductions in all-cause mortality. These advances converted once-fatal conditions into manageable ones. Yet the gain in lifespan has not been matched by a commensurate gain in healthspan. Worldwide, the gap between how long we live and how well we live has widened over the past two decades.
The Global Gap in Numbers
9.6 yrs
Global healthspan–lifespan gap
12.4 yrs
Gap in developed nations
~20%
Of adult life now lived with morbidity
Neurological and neurodegenerative disorders affect 55 million people globally (projected to 139 million by 2050); cardiovascular disease claims ~19 million lives annually; metabolic conditions affect over 500 million. Current medical interventions are optimized for extending lifespan and treating individual diseases, not for targeting the biology of aging itself.
The Singaporean Landscape
Singapore exemplifies both the extraordinary success and the urgent challenge of modern medicine. With the world's highest health-adjusted life expectancy (HALE) at 73.9 years and a life expectancy of 84.9 years, Singapore has achieved more than most nations in adding healthy years of life. Yet even here, the gap between healthspan and lifespan persists and is widening: while life expectancy increased by 8.7 years between 1990 and 2017, healthy life expectancy increased by only 7.2 years over the same period.
Singapore by the Numbers
80%
Of disease burden from aging-related conditions
18.8%
Residents aged 65+ in 2025 (projected 1 in 3 by 2050)
S$59B
Projected national health expenditure by 2030 (from S$21B in 2020)
Nearly 700,000 adults currently live with diabetes (an 11.6% prevalence rate, among the highest in the developed world), and approximately 74,000 older adults live with dementia, over half predicted to be undiagnosed. Without systematic investment in geroscience and translational healthspan research, the trajectory is one of expanded morbidity in the final decades of life.
What the Field Still Lacks
- Interventions that target the underlying biology of aging rather than its downstream manifestations
- Validated therapeutic avenues capable of compressing morbidity into the final months of life
- Robust translational pathways from geroscience discovery to clinical application
- Entrepreneurial scientists equipped to bridge the academia-industry divide in healthspan research
- Equitable access to emerging longevity interventions across diverse populations
The Translation Ecosystem
An Evolving Scientific Landscape
The postdoctoral training system has historically focused on preparing scientists for academic careers. An important opportunity remains underexplored: cultivating an entrepreneurial mindset that enables exceptional researchers to see the broader impact of their work. A postdoctoral fellow who understands intellectual property strategy, sources of capital, and how to assess a druggable target can ask not only "Is this scientifically interesting?" but also "Could this solve a real problem, and what would it take to get there?"
Empowering Postdoctoral Fellows
The founder mindset — identifying unmet needs, assessing feasibility, building teams, and navigating the journey from discovery to application — is not antithetical to rigorous academic science but a natural extension of it. The goal of this RFA is to provide first-in-kind bridging support for the most innovative scientific solutions from visionary postdoctoral fellows.
The Singapore Healthspan Ecosystem
Singapore has built one of Asia's most concentrated healthspan research ecosystems. The NUHS Centre for Healthy Longevity at NUS Medicine aims to enhance healthspan by five years through geroscience and longevity medicine, and in 2025 launched a Clinical Trial Centre to advance precision geromedicine integrating multi-omics, digital health monitoring, and AI-driven biomarker research. The PRECISE-SG100K program — spanning NTU, NUS, A*STAR's Genome Institute of Singapore, and the National Heart Centre — is generating whole genome sequencing and deep phenotyping from 100,000 Singaporeans, Asia's most ambitious population genomics resource for aging research. Singapore's unique multiethnic population represents over 80% of genetic variation across Asia, creating an extraordinary substrate for equity-forward geroscience.
Program Overview ↓
Bridging Discovery and Impact
The Healthspan Imperative fellowship supports postdoctoral scientists at Singapore institutions who are best positioned to change this. We fund researchers who have already made significant contributions and are seeking structured support to translate their findings into real-world applications. This is not a career pivot away from science — it is an expansion of it.
Award Structure
12 mo
Fellowship Duration
Awards are administered through the fellow's home institution. No indirect costs are allowed. The award covers a competitive postdoctoral stipend for 1 year, as fellows embark on their independent scientific careers.
What We Fund
We support postdoctoral research with clear translational potential across six domains:
Fundamental Aging Biology
Senescence, stem cell exhaustion, mitochondrial dysfunction, epigenetic reprogramming, proteostasis, autophagy, inflammaging
Preventive Geroscience
Biomarkers of biological aging, healthspan-extending interventions, exercise and nutrition biology, microbiome-aging axis
Disease-Specific Research
Neurodegeneration, cardiovascular aging, metabolic disease (diabetes, obesity, NASH), cancer survivorship, musculoskeletal aging, immunosenescence
Organ & Tissue Rejuvenation
Cell therapies, tissue engineering, organoid models, partial reprogramming, blood-borne factors, organ-specific aging mechanisms
Translational Tools & Technologies
Drug discovery platforms, high-throughput screening, AI/ML approaches, novel delivery systems, diagnostics and wearables for frailty
Fundamental Molecular Mechanisms
New biology including RNA biology, molecular condensates, structural insights, and novel molecular pathways underlying aging
What We Do Not Fund
Out of Scope
- Pure lifespan extension without healthspan focus
- Projects without preliminary data or a translational pathway
- Anti-aging cosmetics or aesthetic interventions
- Clinical trials or retrospective statistical analyses
- Research that could exacerbate health inequities
- Purely computational or theoretical work without planned experimental validation
- Projects that duplicate existing commercial efforts
Career Stage & Other Mismatches
- Graduate or pre-doctoral students
- Independent faculty members
- Postdocs with <2 or >6 years of experience
- Scientists employed full-time in industry
- Individuals with no intention of transitioning from purely academic roles
- Research with inadequate consideration of equity and access
- Interventions accessible only to wealthy individuals
Key Dates · 2026 Cycle
Deadlines & Timeline
August 15, 2026
Full Application DeadlineSubmit by email to
applications@criticalmassventures.coSubject line:
LastName_FirstName_App_2026 · All materials including reference letters must be received by this date.
August 15, 2026
Full Application Deadline
Complete application and reference letters submitted by email. Subject line must include LastName_FirstName_App_2026. Reference letters: LastName_FirstName_Letter_2026.
Within 90 days
Shortlist Notification
Shortlisted applicants notified within 90 days of receipt. We are unable to send individual rejection notifications.
Following shortlist
Virtual Interview
Shortlisted applicants invited to present their work in pitch deck format and meet the CMV team virtually.
1–2 weeks post-interview
Final Decisions
Finalists notified via email. Award start dates are flexible within 6 months of notification and must be coordinated with the home institution.
Who Should Apply
Eligibility
The Healthspan Imperative is designed for scientists at an inflection point — researchers who have built a strong body of work and are ready to begin thinking seriously about how it reaches the world.
Applicant Requirements
- Hold a PhD, MD, or MD/PhD in a relevant field (biology, biochemistry, neuroscience, pharmacology, genetics, bioengineering, chemical biology, or related disciplines)
- Currently employed as a postdoctoral researcher at an academic institution, research institute, or non-profit research organization within Singapore
- Completed 2–6 years of postdoctoral training at the time of application — extensions considered for parental leave, medical leave, visa delays, or other qualifying circumstances
- Minimum 2 first-author publications in peer-reviewed journals (published or in press)
- Clear career goals articulating a trajectory toward entrepreneurship, biotechnology, or a translational academic role; applicants should plan to transition within approximately 12 months of the award start date
- Appropriate visa or work authorization for the fellowship duration (no citizenship or nationality requirement)
- May not concurrently hold salary support from other individual postdoctoral fellowships; non-salary awards (e.g., conference travel grants) are permissible
- Must disclose all current and pending support
- Must comply with Critical Mass Ventures' Terms and Conditions
Institutional Requirements
Eligible host institutions are research universities, non-profit research institutes, and public healthcare institutions within Singapore, including NUS, NTU, Duke-NUS Medical School, A*STAR research institutes, and their associated hospital systems (National University Health System, SingHealth, National Healthcare Group, and affiliated national specialty centres). Institutions without any postdoctoral training infrastructure are ineligible. For-profit companies are ineligible — applicants must be in academic or non-profit positions.
Although not required, institutions with established postdoctoral training infrastructure — such as exposure to industry mentors, entrepreneurship curriculum, legal and IP consultation, pitch coaching, and venture capital introductions — are an advantage.
Application
How to Apply
Submit a complete application by email to applications@criticalmassventures.co by August 15, 2026. The subject line must include LastName_FirstName_App_2026. Reference letters must be submitted concurrently with the subject line LastName_FirstName_Letter_2026. All files should be in PDF format. Font: Arial, Helvetica, or Times New Roman, 11-point minimum. Margins: 0.5 inch minimum. Line spacing: single. Figures and tables are permitted within page limits.
- Cover Letter (1 page max) — Brief introduction, career goals, and how this fellowship aligns with your translational aspirations
- Curriculum Vitae (5 pages max) — Education, experience, publications, honors, awards, and fellowships
- Research Statement (2 pages max, excluding references) — Scientific context and unmet need, preliminary data supporting translational potential, aims for the fellowship period, and expected deliverables
- Career Development & Transition Plan (1 page max) — Your entrepreneurial vision, concrete transition timeline, and specific skills or knowledge gaps you plan to address
- Two Letters of Support — From PhD advisor and postdoctoral PI/mentor, addressing scientific contributions, translational potential, and commitment to supporting your transition
- Institutional Letter of Support — Confirming applicant eligibility, institutional eligibility, and available resources; signed by department chair or equivalent institutional official
Review Process
1
Administrative Review
Applications screened for completeness and basic eligibility.
2
Scientific Review
Applications evaluated on scientific merit, translational potential, applicant qualifications, and mentor/environment quality. Shortlist notified within 90 days of receipt.
3
Virtual Interview
Shortlisted finalists present their work in a pitch deck format and meet the CMV team virtually.
4
Awards Announced
1–2 fellows selected for 2026. Finalists notified by email within 1–2 weeks of interview. Start dates flexible within 6 months of notification.
Review Criteria
Scientific Merit & Rigor
Quality and significance of preliminary data; soundness of experimental design; feasibility of proposed aims; potential for high-impact contributions; statistical rigor and reproducibility.
Translational Potential
Clarity of pathway from research findings to unmet healthspan need; strength of preliminary validation; competitive landscape analysis and differentiation strategy.
Applicant Qualifications
Publication record and scientific productivity; demonstrated independence and productivity; evidence of translational thinking and entrepreneurial mindset; leadership potential; commitment to a career bridging academia and entrepreneurship.
Mentor & Environment
Quality of mentor letters and commitment to applicant's success; institutional resources and collaborative opportunities; evidence of a genuinely supportive environment for the proposed career transition.
Reporting Requirements
Awardee Obligations
Within 90 days of fellowship completion, awardees submit a 1–2 page final report covering three areas:
Research & Translational Outcomes
Manuscripts published or submitted; patents filed or issued; datasets, tools, or resources generated; presentations and conference abstracts; overall scientific impact.
Career Transition
Position secured or company founded; continuing work on fellowship-funded research; long-term career trajectory.
Impact & Lessons Learned
How the fellowship enabled your transition and entrepreneurial thinking; barriers overcome; advice for future applicants.
Ongoing Engagement
Fellows are expected to remain active members of the CMV community — attending the annual fellow symposium, serving as mentors to future cohorts, participating in program evaluation, and sharing career updates over time (3–5 years post-fellowship).
Acknowledgment
CMV support must be acknowledged in all publications, patents, and presentations using the format: "This work was supported by the Critical Mass Ventures Healthspan Imperative [award number]." Copies of all acknowledging publications should be sent to applications@criticalmassventures.co, and fellows are asked to include the fellowship in their ORCID and researcher profile systems.
Full Application Package
Download the RFA
The complete Request for Applications document includes all program details, eligibility requirements, application guidelines, and review criteria in a single PDF suitable for sharing with colleagues and mentors.
This RFA is specific to Singapore. For the California RFA, click here.
FAQs
Can I apply if I'm planning to start a company?
Yes — we strongly encourage entrepreneurial applicants. Your career development plan should outline your company formation thinking, including the problem you're solving, your current stage, and concrete next steps.
What if I haven't identified a specific industry position yet?
That's expected. Focus on career direction, the therapeutic area you're most interested in, and concrete steps you plan to take to explore opportunities. Clarity of intent matters more than a locked-in plan.
I'm in my 6th year of postdoc. Am I eligible?
Possibly. Contact us before applying to discuss your situation. Extensions to the postdoctoral period for parental leave, medical leave, or visa delays are considered on a case-by-case basis.
Do I need to be a Singapore citizen or permanent resident?
No. There is no citizenship or nationality requirement. You must be employed by an eligible Singapore institution and hold appropriate work authorization for the duration of the fellowship. Visa delays that extended your postdoctoral period may be considered for eligibility extensions.
Which Singapore institutions are eligible?
Eligible institutions include research universities, non-profit research institutes, and public healthcare institutions within Singapore: NUS, NTU, Duke-NUS Medical School, A*STAR research institutes, and their associated hospital systems (National University Health System, SingHealth, National Healthcare Group, and affiliated national specialty centres). For-profit companies are not eligible — applicants must be in academic or non-profit positions.
Do I need to transition to a position in Singapore after the fellowship?
No. You may transition to industry or entrepreneurship anywhere in the world. Your application should articulate how your target region's ecosystem supports your translational goals.
Will my application be disadvantaged if English is not my first language?
No. Applications must be submitted in English, and we welcome applicants from all linguistic and cultural backgrounds. Clear communication of your science and vision is what matters.
My research is early stage but has strong translational potential. Should I apply?
Preliminary data is essential to a competitive application. If you are still generating foundational proof-of-concept results, we encourage you to apply in a future cycle once you have data that supports the translational pathway you envision. Risky and long-term projects are welcome, but preliminary data must be present.
Can I hold this fellowship alongside another award?
You may not concurrently hold salary support from other individual postdoctoral fellowships, but you may have received such support in the past. Non-salary awards such as travel grants or conference funding are generally permissible. Contact us to discuss your specific situation before applying.
Is purely computational or theoretical work eligible?
Purely computational or theoretical work without any experimental component is not eligible. However, projects that are primarily computational but include planned collaborations for experimental validation are welcome. Please describe those plans clearly in your research statement.
What if my career transition takes longer than the fellowship period?
We understand that transitions take time. The fellowship is designed to catalyze and accelerate your path, not to complete it. We expect fellows to have made documented progress during the fellowship year and to remain engaged with the CMV community over the longer term.
Equal Opportunity
Diversity, Equity & Inclusion
Critical Mass Ventures is committed to diversity, equity, and inclusion in all aspects of our funding programs globally. We do not discriminate on the basis of race, color, national origin, nationality, sex, disability, age, religion, sexual orientation, gender identity, veteran status, or any other characteristic protected by law. We especially encourage applications from individuals from groups underrepresented in science globally and from diverse backgrounds and institutions within Singapore.